United Kingdom· GB-APID-43146511000001102
Ocrevus 920mg/23ml solution for injection vials
A ocrelizumab product containing ocrelizumab, registered in United Kingdom by Roche Products Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Ocrelizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AG08 (ocrelizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Ocrelizumab · ATC L04AG08
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ocrelizumab costs, country by country.
Normalised to the WHO defined daily dose (3.29 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ocrelizumab · price per daily dose (3.29 mg)
USD · FX 28 Sept 2026
- CH Switzerland$54.58
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Ocrelizumab
- Manufacturer
- Roche Products Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AG08
- ATC class
- Ocrelizumab
- Defined daily dose
- 3.29 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin07613326075763
- gtin7613326075763
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
328 interactions on record for ocrelizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ocrelizumab · interactions on record
328 records
- 27 severe
- 294 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ocrelizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandOcrevusAbacus Medicine A/S
- CzechiaOCREVUSRoche Registration GmbH, Grenzach-Wyhlen
- SpainOCREVUS 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- BelgiumOcrevus 300 mgRoche Registration
- SwitzerlandOcrevus subkutan 920 mg/23 ml, InjektionslösungRoche Pharma (Schweiz) AG
- NetherlandsOcrevus 300 mg concentraat voor oplossing voor infusieRoche Registration GmbH
- PolandOcrevusRoche Registration GmbH
- SwedenOcrevus 300 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ocrevus
- Liechtenstein · Ocrevus
- Norway · Ocrevus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d12d06b2-1fd5-4112-9c0d-95b202928d4f GET /v1/drugs/d12d06b2-1fd5-4112-9c0d-95b202928d4f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "43146511000001102",
"desc": "Ocrevus 920mg/23ml solution for injection vials (Roche Products Ltd)",
"form": "Solution for injection",
"vpid": "43159211000001106",
"source": "dmd",
"vtm_id": "776963008",
"strength": "40 mg",
"substance": "Ocrelizumab",
"ingredient": "Ocrelizumab",
"supplier_code": "2085201000001100"
}See everything about ocrelizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.